Literature DB >> 31243774

Clotrimazole troches can alter everolimus pharmacokinetics in post-transplant patients: A case report.

Takaya Uno1,2,3, Kyoichi Wada4, Sachi Matsuda1, Megumi Ikura1, Hiromi Takenaka1, Nobue Terakawa1, Akira Oita1, Satoshi Yokoyama2,3, Atsushi Kawase5, Kouichi Hosomi2,3, Mitsutaka Takada2,3.   

Abstract

Entities:  

Year:  2019        PMID： 31243774      PMCID： PMC6710514          DOI： 10.1111/bcp.14017

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  19 in total

1.  Duration of drug interactions: putative time courses after mechanism-based inhibition or induction of CYPs.

Authors:  Hiromitsu Imai; Tsutomu Kotegawa; Kyoichi Ohashi
Journal:  Expert Rev Clin Pharmacol       Date:  2011-07       Impact factor: 5.045

2.  Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction.

Authors:  David Shitrit; Jacob E Ollech; Ayelet Ollech; Ilana Bakal; Milton Saute; Gideon Sahar; Mordechai R Kramer
Journal:  J Heart Lung Transplant       Date:  2005-10-14       Impact factor: 10.247

Review 3.  Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.

Authors:  Fuad Shihab; Uwe Christians; Lonnie Smith; Jason R Wellen; Bruce Kaplan
Journal:  Transpl Immunol       Date:  2014-05-24       Impact factor: 1.708

4.  Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications.

Authors:  J M Kovarik; C H Hsu; L McMahon; S Berthier; C Rordorf
Journal:  Clin Pharmacol Ther       Date:  2001-09       Impact factor: 6.875

5.  Blood concentrations of everolimus are markedly increased by ketoconazole.

Authors:  J M Kovarik; D Beyer; M N Bizot; Q Jiang; M Shenouda; R L Schmouder
Journal:  J Clin Pharmacol       Date:  2005-05       Impact factor: 3.126

6.  Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam.

Authors:  Stacy S Shord; Lingtak-Neander Chan; Joseph R Camp; Eva M Vasquez; Hyun-Young Jeong; Robert E Molokie; Charles L Baum; Hui Xie
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of everolimus.

Authors:  Gabriele I Kirchner; Ivo Meier-Wiedenbach; Michael P Manns
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  The enzymatic basis of drug-drug interactions with systemic triazole antifungals.

Authors:  Yasmine Nivoix; Dominique Levêque; Raoul Herbrecht; Jean-Claude Koffel; Laurence Beretz; Genevieve Ubeaud-Sequier
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

9.  Latex-enhanced turbidimetric immunoassay for everolimus in whole blood using the Nanopia TDM everolimus assay with the JCA-BM6010 automatic analyzer.

Authors:  Keiko Mori; Shigeki Kimura; Masahiko Matsui; Etsuji Suehisa; Yoh Hidaka; Norihide Fukushima
Journal:  Ther Drug Monit       Date:  2014-10       Impact factor: 3.681

10.  Co-administration of ketoconazole to tacrolimus-treated kidney transplant recipients: a prospective randomized study.

Authors:  Khalid Farouk el-Dahshan; Mohamed Adel Bakr; Ahmed Farouk Donia; Ali el-Sayed Badr; Mohamed Abdel-Kader Sobh
Journal:  Nephrol Dial Transplant       Date:  2004-03-19       Impact factor: 5.992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.